Research ArticleArticle
Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials
Xenofon Baraliakos, Andrew S. Koenig, Heather Jones, Annette Szumski, David Collier and Eustratios Bananis
The Journal of Rheumatology June 2015, jrheum.141278; DOI: https://doi.org/10.3899/jrheum.141278
Xenofon Baraliakos
Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA. This posthoc analysis was funded by Pfizer Inc. The studies described herein were funded by Wyeth, which was acquired by Pfizer Inc. in October 2009, and by Amgen Inc. Medical writing support was provided by Patricia McChesney and John Bilbruck of Engage Scientific Solutions and funded by Pfizer Inc. X. Baraliakos has received compensation for participation in advisory boards, speaker’s honoraria, or unrestricted research grants from Pfizer. A.S. Koenig, H. Jones, and E. Bananis are employees of Pfizer Inc. A. Szumski is an employee of inVentiv Health and a paid contractor to Pfizer Inc. for providing statistical support for this study and the development of this manuscript. D. Collier is an employee of Amgen. X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. Address correspondence to Dr. X. Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Claudiusstr. 45, 44649 Herne, Germany. E-mail: baraliakos@me.com. Accepted for publication March 31, 2015.
Andrew S. Koenig
Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA. This posthoc analysis was funded by Pfizer Inc. The studies described herein were funded by Wyeth, which was acquired by Pfizer Inc. in October 2009, and by Amgen Inc. Medical writing support was provided by Patricia McChesney and John Bilbruck of Engage Scientific Solutions and funded by Pfizer Inc. X. Baraliakos has received compensation for participation in advisory boards, speaker’s honoraria, or unrestricted research grants from Pfizer. A.S. Koenig, H. Jones, and E. Bananis are employees of Pfizer Inc. A. Szumski is an employee of inVentiv Health and a paid contractor to Pfizer Inc. for providing statistical support for this study and the development of this manuscript. D. Collier is an employee of Amgen. X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. Address correspondence to Dr. X. Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Claudiusstr. 45, 44649 Herne, Germany. E-mail: baraliakos@me.com. Accepted for publication March 31, 2015.
Heather Jones
Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA. This posthoc analysis was funded by Pfizer Inc. The studies described herein were funded by Wyeth, which was acquired by Pfizer Inc. in October 2009, and by Amgen Inc. Medical writing support was provided by Patricia McChesney and John Bilbruck of Engage Scientific Solutions and funded by Pfizer Inc. X. Baraliakos has received compensation for participation in advisory boards, speaker’s honoraria, or unrestricted research grants from Pfizer. A.S. Koenig, H. Jones, and E. Bananis are employees of Pfizer Inc. A. Szumski is an employee of inVentiv Health and a paid contractor to Pfizer Inc. for providing statistical support for this study and the development of this manuscript. D. Collier is an employee of Amgen. X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. Address correspondence to Dr. X. Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Claudiusstr. 45, 44649 Herne, Germany. E-mail: baraliakos@me.com. Accepted for publication March 31, 2015.
Annette Szumski
Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA. This posthoc analysis was funded by Pfizer Inc. The studies described herein were funded by Wyeth, which was acquired by Pfizer Inc. in October 2009, and by Amgen Inc. Medical writing support was provided by Patricia McChesney and John Bilbruck of Engage Scientific Solutions and funded by Pfizer Inc. X. Baraliakos has received compensation for participation in advisory boards, speaker’s honoraria, or unrestricted research grants from Pfizer. A.S. Koenig, H. Jones, and E. Bananis are employees of Pfizer Inc. A. Szumski is an employee of inVentiv Health and a paid contractor to Pfizer Inc. for providing statistical support for this study and the development of this manuscript. D. Collier is an employee of Amgen. X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. Address correspondence to Dr. X. Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Claudiusstr. 45, 44649 Herne, Germany. E-mail: baraliakos@me.com. Accepted for publication March 31, 2015.
David Collier
Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA. This posthoc analysis was funded by Pfizer Inc. The studies described herein were funded by Wyeth, which was acquired by Pfizer Inc. in October 2009, and by Amgen Inc. Medical writing support was provided by Patricia McChesney and John Bilbruck of Engage Scientific Solutions and funded by Pfizer Inc. X. Baraliakos has received compensation for participation in advisory boards, speaker’s honoraria, or unrestricted research grants from Pfizer. A.S. Koenig, H. Jones, and E. Bananis are employees of Pfizer Inc. A. Szumski is an employee of inVentiv Health and a paid contractor to Pfizer Inc. for providing statistical support for this study and the development of this manuscript. D. Collier is an employee of Amgen. X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. Address correspondence to Dr. X. Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Claudiusstr. 45, 44649 Herne, Germany. E-mail: baraliakos@me.com. Accepted for publication March 31, 2015.
Eustratios Bananis
Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA. This posthoc analysis was funded by Pfizer Inc. The studies described herein were funded by Wyeth, which was acquired by Pfizer Inc. in October 2009, and by Amgen Inc. Medical writing support was provided by Patricia McChesney and John Bilbruck of Engage Scientific Solutions and funded by Pfizer Inc. X. Baraliakos has received compensation for participation in advisory boards, speaker’s honoraria, or unrestricted research grants from Pfizer. A.S. Koenig, H. Jones, and E. Bananis are employees of Pfizer Inc. A. Szumski is an employee of inVentiv Health and a paid contractor to Pfizer Inc. for providing statistical support for this study and the development of this manuscript. D. Collier is an employee of Amgen. X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. Address correspondence to Dr. X. Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Claudiusstr. 45, 44649 Herne, Germany. E-mail: baraliakos@me.com. Accepted for publication March 31, 2015.
Data supplements
Data Supplement
Data Supplement
Files in this Data Supplement:
- Data Supplement - Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials
Xenofon Baraliakos, Andrew S. Koenig, Heather Jones, Annette Szumski, David Collier, Eustratios Bananis
The Journal of Rheumatology Jun 2015, jrheum.141278; DOI: 10.3899/jrheum.141278
Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials
Xenofon Baraliakos, Andrew S. Koenig, Heather Jones, Annette Szumski, David Collier, Eustratios Bananis
The Journal of Rheumatology Jun 2015, jrheum.141278; DOI: 10.3899/jrheum.141278